United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Friday, October 30th. The stock was sold at an average price of $600.09, for a total transaction of $5,700,855.00. Following the completion of the sale, the chief executive officer owned 324,443 shares of the company's stock, valued at $194,694,999.87. This trade represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
United Therapeutics Trading Down 0.4%
NASDAQ:UTHR opened at $596.13 on Tuesday. United Therapeutics Corporation has a twelve month low of $430.02 and a twelve month high of $609.99. The company has a market cap of $25.57 billion, a PE ratio of 21.33, a P/E/G ratio of 4.25 and a beta of 0.49. The company's 50 day moving average is $528.76 and its two-hundred day moving average is $531.14.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.86 by $0.41. The business had revenue of $783.30 million during the quarter, compared to analysts' expectations of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business's quarterly revenue was down 1.9% on a year-over-year basis. During the same quarter last year, the company posted $6.41 earnings per share. As a group, analysts expect that United Therapeutics Corporation will post 26.09 EPS for the current fiscal year.
United Therapeutics announced that its Board of Directors has approved a share buyback program on Thursday, October 22nd that permits the company to repurchase $2 billion in outstanding shares. This buyback authorization permits the biotechnology company to buy up to 8.3% of its stock through open market purchases. Share buyback programs are generally an indication that the company's leadership believes its shares are undervalued.
Wall Street Analysts Forecast Growth
Several analysts have weighed in on the company. UBS Group set a $725.00 price target on United Therapeutics in a research note on Monday, October 19th. Royal Bank Of Canada reduced their price objective on United Therapeutics from $708.00 to $697.00 and set an "outperform" rating for the company in a research note on Thursday, October 22nd. The Goldman Sachs Group reaffirmed a "sell" rating and set a $368.00 target price on shares of United Therapeutics in a report on Thursday, October 15th. Morgan Stanley upped their target price on United Therapeutics from $515.00 to $566.00 and gave the company an "equal weight" rating in a research report on Wednesday, October 7th. Finally, Bank of America dropped their target price on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating on the stock in a research report on Friday, July 10th. Twelve research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $667.07.
View Our Latest Stock Analysis on United Therapeutics
Institutional Investors Weigh In On United Therapeutics
Several hedge funds have recently bought and sold shares of the stock. Arjuna Capital increased its holdings in shares of United Therapeutics by 2.8% during the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company's stock valued at $393,000 after purchasing an additional 18 shares in the last quarter. Sage Rhino Capital LLC boosted its holdings in United Therapeutics by 5.1% during the first quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company's stock worth $281,000 after buying an additional 23 shares in the last quarter. Bryn Mawr Trust Advisors LLC boosted its holdings in United Therapeutics by 5.4% during the first quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company's stock worth $276,000 after buying an additional 24 shares in the last quarter. Meeder Advisory Services Inc. boosted its holdings in United Therapeutics by 4.1% during the first quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company's stock worth $392,000 after buying an additional 26 shares in the last quarter. Finally, Kera Capital Partners Inc. grew its position in United Therapeutics by 6.1% during the first quarter. Kera Capital Partners Inc. now owns 471 shares of the biotechnology company's stock valued at $279,000 after buying an additional 27 shares during the period. Hedge funds and other institutional investors own 94.08% of the company's stock.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company's portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.
The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
